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A recent joint meeting was held on January 30, 2014, with the US Food and Drug Administration (FDA), National Cancer Institute
(NCI), clinical scientists, imaging experts, pharmaceutical and biotech companies, clinical trials cooperative groups, and patient ad-
vocate groups to discuss imaging endpoints for clinical trials in glioblastoma. This workshop developed a set of priorities and action
items including the creation of a standardized MRI protocol for multicenter studies. The current document outlines consensus rec-
ommendations for a standardized Brain Tumor Imaging Protocol (BTIP), along with the scientific and practical justifications for these
recommendations, resulting from a series of discussions between various experts involved in aspects of neuro-oncology neuroim-
aging for clinical trials. The minimum recommended sequences include: (i) parameter-matched precontrast and postcontrast
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inversion recovery-prepared, isotropic 3D T1-weighted gradient-recalled echo; (ii) axial 2D T2-weighted turbo spin-echo acquired
after contrast injection and before postcontrast 3D T1-weighted images to control timing of images after contrast administration;
(iii) precontrast, axial 2D T2-weighted fluid-attenuated inversion recovery; and (iv) precontrast, axial 2D, 3-directional diffusion-
weighted images. Recommended ranges of sequence parameters are provided for both 1.5 T and 3 T MR systems.
Keywords: Brain Tumor Imaging Protocol, clinical trials, glioblastoma, MRI.
Need for Increased Development of Therapeutics
for Treating Brain Tumors
Approximately 67 900 new primary CNS tumors are diagnosed
each year in the United States (21 per 100 000 persons), of
which 44 910 are malignant.1 Of these newly diagnosed
tumors, approximately 28% are gliomas, which constitute 80%
of all malignant primary brain tumors.1 Glioblastoma, the most
common and aggressive type of glioma, is the focus of this docu-
ment for 2 reasons. First, it is the most common form of high-
grade glioma, accounting for 54% of all gliomas and 45% of
all malignant primary CNS tumors;1 thus, it is a high priority
area for therapeutic development. Second, glioblastoma is one
of the most complex and treatment-resistant brain tumors;
therefore, improvements in drug development and measure-
ment of tumor response to therapy in glioblastoma may allow
advancement of these efforts for other types of brain tumors.
The current standard of care for newly diagnosed glioblasto-
ma patients involves maximum safe surgical resection, followed
by radiotherapy plus concomitant and adjuvant temozolomide,2
but this treatment affords only a median survival of 14–16
months,3–6 and fewer than 10% of patients survive 5 years be-
yond diagnosis.7 Furthermore, very few therapeutic options exist
for recurrent disease since patients with prior temozolomide
exposure have progression-free survival (PFS) rates at 6 months
of 20%–40% regardless of chemotherapeutic intervention (eg,
nitrosoureas, temozolomide rechallenge, or bevacizumab).5,6,8
Thus, there is an urgent need for drug development in recurrent
glioblastoma.
Role of Imaging in Brain Tumor Clinical Trials
Although overall survival (OS) is considered the gold standard
for determining whether a cancer treatment is effective, OS
may not directly reflect the specific impact of particular treat-
ment regimens because of the confounding effects of known
prognostic factors (eg, age, tumor size, neurological status),
use of additional therapies prior to or after the therapy of inter-
est, and other health-related factors.9,10 Hence, PFS and dura-
ble objective response rate (ORR) are considered valuable end
points for determining the relative value of a given treatment.11
(Note that PFS also suffers from the impact of prognostic fac-
tors.) Identifying response and progression has traditionally
been based on neuroimaging supported by clinical observation12
with limited utility of serum or cerebrospinal fluid markers of
disease for gliomas. However, surrogate measures of tumor
burden (eg, area with contrast uptake) can suffer from issues
associated with nonspecificity of the surrogate, measurement
variability, false positives, and discordance in radiographic inter-
pretation between observers.13 Therefore, Response Assessment
In Neuro-Oncology (RANO) needs refinement to minimize intrinsic
errors and to improve the accuracy of determining true response
to a particular therapy.
A joint meeting was held on January 30, 2014, among the
Food and Drug Administration (FDA), National Cancer Institute
(NCI), clinical scientists, imaging experts, clinical trials coopera-
tive groups, representatives from pharmaceutical and biotech-
nology companies, and patient advocate groups to discuss
endpoints for clinical trials in glioblastoma.9,10,14,15 With only
4 drugs for glioblastoma having been approved by the FDA
over the past 30 years (ie, nitrosoureas, carmustine, temozolo-
mide, and bevaczumab), the significant costs associated with
large studies, and few survival-extending breakthroughs,
there is a need to quickly identify effective experimental thera-
pies with a minimum of invested time and cost. For example, 3
large phase 3 trials were completed, based on promising phase
3 data, which failed to significantly extend OS.5,6,16 These fail-
ures highlight the need to optimize the use of imaging as a sur-
rogate tool to better understand the response to novel
therapeutics. To address these needs, a key recommendation
arising from this workshop, with the encouragement of the
FDA, was the development of a set of priorities and action
items including: (i) standardization of the MRI protocol for
multicenter studies; (ii) validating the use of volumetric analysis
of T1 subtraction maps for defining treatment response and
failure for use in drug approval studies; and (iii) subsequent re-
evaluation of the current RANO criteria with an effort to inte-
grate standardized imaging and quantitative evaluations.
These priorities set forth by the thought leaders in the neuro-
oncology community, the Jumpstarting Brain Tumor Drug
Development Coalition (consisting of the National Brain Tumor
Society [NBTS], Society for Neuro-Oncology [SNO], Musella
Foundation for Brain Tumor Research, Accelerate Brain Cancer
Cure [ABC2]), the FDA, and NCI represent the procedures neces-
sary for validating and building confidence in order to use quan-
titative imaging surrogates as endpoints in glioblastoma
clinical trials for drugs. Indeed, Dr. Richard Pazdur, Director of
the FDA Office of Hematology and Oncology Products, shared,
“During our participation in the Brain Tumor Endpoints Work-
shop, we identified standardization of imaging data acquisition
and analysis as a step towards increasing the reliability of radio-
graphic endpoints in brain tumor clinical trials, and improving
the ability to assess the impact of therapies in neuro-oncology.”
The current document outlines the consensus recommen-
dations for a standardized Brain Tumor Imaging Protocol
(BTIP), along with the scientific and practical justifications for
these recommendations, resulting from a series of discussions
between various experts in neuro-oncology neuroimaging for
clinical trials. The recommendations in the current document
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are in direct response to the priorities that resulted from the
workshop in January 2014, and are supported by the RANO
working group.
Need for Imaging Standardization for Better Response
Measures
In multicenter MRI studies, the heterogeneity of MR scanners and
parameters (eg, field strength, gradient system, manufacturer,
sequences) must be considered. It is well known that even
minor differences in hardware or sequence timing may result in
significant changes in image contrast. Lesion contrast is also de-
pendent on the magnetic field strength of the scanner,17,18 with
higher field strengths showing higher contrast-to-noise com-
pared with lower field strength scanners (eg, 3 T vs 1.5 T). More-
over, a variety of MR protocols are commonly used for the same
purpose, further hindering interpretation of imaging results from
different treatment centers in the absence of tight control and
standardization of image acquisition parameters.
Leveraging Lessons From the Alzheimer’s Disease
Neuroimaging Initiative (ADNI) Effort to Standardize
Structural MRI Acquisition
Neuroimaging remains at the forefront of medical imaging
technology and research; however, a lack of benchmarked
standard acquisition protocols combined with rapidly evolving
technologies can limit the ability to combine data in a multi-
center fashion. This became readily apparent when attempting
to study subtle structural changes in the brain related to degen-
erative diseases such as Alzheimer’s disease. The subtle differ-
ences in acquisition parameters and sequences, along with
variations in MR system technologies and hardware, resulted
in significant measurement discordance across centers, mask-
ing the effects of the disease. To standardize image acquisition
to better understand Alzheimer’s disease, the Alzheimer’s Dis-
ease Neuroimaging Initiative (ADNI) was launched in October
2004.19,20 This was a landmark effort to standardize brain im-
aging across clinical centers in the United States and Canada.
ADNI was funded as a large public-private partnership between
the National Institutes of Aging (NIA) and the National Institute
of Biomedical Imaging and Bioengineering (NIBIB) of the
National Institutes of Health (NIH), MR system manufacturers,
several pharmaceutical companies (Pfizer, Wyeth, Eli Lilly,
Merck, GlaxoSmithKline, AstraZeneca, Novartis, Eisai, Elan, For-
est Laboratories, Bristol Meyers Squibb), and foundations
(Alzheimer’s Association, Institute for the Study of Aging).
One of the primary, tangible deliverables from ADNI was a
standardized anatomic MRI protocol for accurate and reproduc-
ible brain imaging that is uniform across the major MR system
manufacturers.21 The ADNI initiative produced a vendor-
neutral, standardized, inversion-recovery (IR) prepped volumet-
ric T1-weighted gradient echo sequence for quantification of
volumetric changes in brain structures, and a dual echo,
proton-density T2-weighted turbo spin-echo sequence for
quantifying pathologic changes via estimates of tissue T2.22
The use of T1-weighted and T2-weighted images are critically
important for brain tumor response assessment, as outlined in
the RANO recommendations and discussed further in the
current document. Since the imaging biomarkers and MRI
pulse sequences of interest in ADNI are very similar to those re-
quired for measurement of brain tumor response to therapy,
many of the ADNI recommendations were focused on the
goal of expediting the process of developing a standardized an-
atomic MRI protocol for brain tumors and avoiding many of the
pitfalls and expenses encountered by ADNI.
Development of MR Image Acquisition Standardization
in the European Organization of Research and
Treatment of Cancer Brain Tumor Group
The European Organization of Research and Treatment of Can-
cer (EORTC) Brain Tumor Group (BTG) acknowledged the need
for standardization of MR image acquisition in the context of
clinical trials in 2010. A core group of BTG members including
neuroradiologists, neuro-oncologists and, MR physicists, with
support from EORTC headquarters, developed both a basic
and an advanced MR protocol. The basic protocol consisted of
the core imaging sequences required to assess treatment re-
sponse according to the RANO criteria, (ie, T1- and T2-weighted
sequences). The basic protocol was deemed mandatory for all
participating sites, while the advanced protocol was to be
adopted by selected sites only. For both protocols, a balance
was sought between feasibility and image quality. Since the
protocol was required to be implemented in all participating
sites throughout Europe, it needed to be feasible both in
terms of available equipment and scan time. The main issue
encountered when trying to implement this protocol was that
sites were traditionally not selected on the basis of imaging fa-
cilities but rather on their ability to recruit and enroll patients in
clinical trials. Radiologists are not commonly involved in the im-
peding EORTC trials, and generally no funding for any additional
scan time is available in investigator-initiated trials. The proto-
col therefore needed to fit seamlessly into the clinical routine,
while ensuring sufficient image quality. The development
phase was concluded in 2012, after which the protocols were
implemented in 2 newly opened trials: EORTC-26101 and
EORTC-26091 (TAVAREC). General acceptance of the protocol
was high, and only one site indicated that they would be unable
to adhere to the protocol. After the initial rollout phase, major
protocol violations were reduced markedly to less than 10%.
The excellent adherence indicates that the protocol could be
implemented into the clinical routine without losing sites for re-
cruitment, with a pragmatic but rigorous quality assurance
mechanism in place (which is crucial in this setting). The BTIP
described in the current document has drawn from the
EORTC-BTG experience, and care has been taken to maintain
the same level of feasibility.
Philosophical Considerations and Compromises
During the course of discussions with panel experts, many phil-
osophical concepts and approaches were considered, resulting
in specific notable compromises. The concept of an “ideal” or
“optimized” protocol is elusive and ill-defined in terms of the re-
quired performance measures used for optimization. Instead, a
pragmatic approach was considered, striving for a balance be-
tween an ideal protocol, which may be available only on select
high-performance systems or at state-of-the-art academic
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centers, and a protocol that could reach large-scale compli-
ance and acceptance from the community, including interna-
tional participants. The goal of the initiative was not only to
define a protocol for trials with reimbursement for imaging by
the sponsor but also for use in investigator-initiated trials with-
out funding or even in daily practice. Thus the suggested proto-
col needs to approach that used in clinical practice in terms of
examination time and types of sequences. The concept of
tightly controlling acquisition parameters to limit variability
was felt to be desirable; however, this clearly must be balanced
against the practicality of employing such regulations at the
large numbers of centers with variable imaging capabilities.
With MR systems currently in use at large institutions dating
back more than 20 years, a degree of flexibility was desired in
order to allow these centers to still be involved in future clinical
trials without significantly affecting image quality or perfor-
mance. In short, perfect can be the enemy of good enough,
and what is required here is an MRI protocol that is both ade-
quate in terms of quality and feasibility at the majority of insti-
tutions. Additionally, we attempted to think progressively and
consider aspects related to the future of imaging response as-
sessment, namely the potential use of volumetry (compared
with current bidirectional assessments) for determining re-
sponse, duration of response, and the potential for quantifying
subclinical measures of tumor response including growth kinet-
ics, use of T1 subtraction maps (compared with current evalu-
ations on postcontrast T1-weighted images) to increase lesion
conspicuity and more accurately quantify enhancing tumor
burden, and the use of dual echo proton-density/T2-weighted
images for estimating tissue T2 (instead of relying solely on
T2-weightedimages (which are relatively nonspecific for delin-
eating nonenhancing tumor from vasogenic edema). Because
many new and promising pulse sequences may be more widely
available in the future, the panel recommends that the current
protocol serve as a well-needed benchmark for comparison of
future sequences and imaging systems. Any new addition to
the protocol should be evaluated for its potential to improve
treatment evaluation with OS as the key endpoint. Lastly, the
current recommended protocol was designed to obtain neces-
sary content while minimizing total scan time to ideally 30 min-
utes of actual image acquisition because patient tolerance in
this population can be a challenge, and patient throughput is
a primary concern for most imaging centers.
Recommended MRI Acquisition Protocols
The recommended minimum requirements for MR image ac-
quisition for use in brain tumor clinical trials are outlined in
Table 1. This protocol is applicable to both 1.5 T and 3 T scan-
ners, although some modifications to scan parameters may
be needed to ensure similar signal-to-noise ratio (SNR) and
contrast-to-noise ratio (CNR) in the resulting images. Additional
examples of compliant MR acquisition protocols specific to 3 T
and 1.5 T scanners are found in Tables 2 and 3. The total
amount of actual scan time (image acquisition only) was
benchmarked at approximately 21 minutes and 30 seconds
on a 3 T Siemens Skyra with parallel imaging, suggesting
that the entire acquisition including setup and teardown can
be performed in approximately 30 minutes using current 3 T
systems. Key elements of this protocol include: (i) a precontrast,
3-dimensional, isotropic, IR-prepped T1-weighted gradient
echo (IR-GRE) sequence; (ii) an axial, 2-dimensional T2-weighted
fluid-attenuated inversion recovery (FLAIR) sequence obtained
using a turbo-spin-echo (TSE) readout; (iii) an axial, 2-dimensional,
3-directional (isotropic) diffusion-weighted imaging (DWI)
sequence obtained using echoplanar (EPI) or radial acquisition;
(iv) an axial, 2-dimensional T2-weighted TSE sequence (dual
echo preferred, but not required); and (v) a postcontrast,
3-dimensional, isotropic, T1-weighted IR-GRE sequence with
matching acquisition parameters to precontrast T1-weighted
images.
Precontrast and Postcontrast Volumetric, IR-Prepared
T1-Weighted Gradient Echo MRI
The use of precontrast and postcontrast images (CT or MRI)
has been the standard for detection, delineation, and re-
sponse assessment of malignant brain tumors for more
than 60 years. The most aggressive brain tumors are charac-
terized by angiogenesis, and studies have demonstrated a
clear association between neovascularization and increased
malignancy.23,24 This new vasculature is structurally abnor-
mal, resulting in contrast agent leakage from the vascular to
the extravascular, extracellular space and increased conspicu-
ity of lesions on imaging in the general vicinity of active tumor.
T1-weighted MRI sequences, used after administration of a
contrast agent that shortens T1 relaxation time, are the stan-
dard for response assessment due to better soft tissue con-
trast and lack of ionizing radiation with MRI as opposed to
contrast-enhanced CT.
The acquisition of 3-dimensional, isotropic T1-weighted
images allows for potential improvements in response assess-
ment, including detection of smaller lesions, use of volumetric
measurements of enhancing tumor burden, and better align-
ment of tumor regions on subsequent follow-up examinations.
Data from the literature clearly indicate that volumetric mea-
surements of tumor burden and response are equal to—or bet-
ter than—1D/2D measurements of tumor extent, especially
with tumors that are irregular in shape such as glioblasto-
ma.13,25 – 32 A higher interobserver variability has been noted
when assessments are made using bidirectional or unidirec-
tional measurements compared with volumetric quantita-
tion.33 – 37 Volumetric changes observed during therapy may
be useful for quantifying trends in tumor growth or response
that provide insight into whether a treatment is having an ef-
fect on the tumor despite lack of clear radiographic response
according to the RANO criteria.38 Additionally, a significant lim-
itation of comparisons in tumor size performed on relatively
thick (3–5 mm) 2-dimensional T1-weighted images includes
the effects of slightly different slice prescriptions (eg, different
head tilt) on the ability to properly align similar slices for
side-by-side comparison.39 Acquisition of 3-dimensional isotro-
pic T1-weighted images will provide the ability to easily register
or align images from subsequent follow–up time points to the
baseline scans for more accurate comparison of tumor size.
Also, acquisition of 3-dimensional isotropic T1-weighted imag-
es allows for resampling image data along different orienta-
tions without the need for additional MR acquisitions (eg, in
the sagittal or coronal planes, which are often desired for sur-
gical and radiation therapy planning).
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Table 1. Minimum standard 1.5 T & 3 T MRI protocol
3D T1w Preb Ax 2D FLAIRj Ax 2D DWI Ax 2D T2wh,i 3D T1w Postb
Sequence IR-GREe,f TSEc SS-EPIg
C
o
n
t
r
a
s
t
I
n
j
e
c
t
i
o
n
a
TSEc IR-GREe,f
Plane Sagittal/axial Axial Axial Axial Sagittal/axial
Mode 3D 2D 2D 2D 3D
TR [ms] 2100m .6000 .5000 .2500 2100m
TE [ms] Min 100–140 Min 80–120 Min
TI [ms] 1100n 2000–2500k 1100n
Flip angle 108–158 908/≥1608 908/1808 908/≥1608 108–158
Frequency ≥172 ≥256 ≥128 ≥256 ≥172
Phase ≥172 ≥256 ≥128 ≥256 ≥172
NEX ≥1 ≥1 ≥1 ≥1 ≥1
FOV 256 mm 240 mm 240 mm 240 mm 256 mm
Slice thickness ≤1.5 mm ≤4 mml ≤4 mml ≤4 mml ≤1.5 mm
Gap/spacing 0 0 0 0 0
Diffusion optionsp b¼ 0, 500, 1000 s/mm2 ≥3 directions
Parallel imaging Up to 2x Up to 2x Up to 2x Up to 2x Up to 2x
Scan time (approx)
[benchmarked on 3 T Skyra]
5–10 min [5:49 for 1 mm
isotropic]
4–8 min [3:22 for 2D
FLAIR]
2–4 min [1:22 for 3 direction DWI and 3
b-values]
4–8 min [5:10 for dual
echo]
5–10 min [5:49 for 1 mm
isotropic]
Abbreviations: 2DFL, 2-dimensional FLASH (fast low angle shot) gradient recalled echo; 3D, 2-dimensional; A/P, anterior to posterior; ADC, apparent diffusion coefficient; Ax, Axial; DSC,
dynamic susceptibility contrast; DWI, diffusion-weighted imaging; EPI, echo-planar imaging; FLAIR, fluid-attenuated inversion recovery; FOV, field of view; GE-EPI, gradient-echo
echo-planar imaging; IR-GRE, inversion-recovery gradient-recalled echo. MPRAGE, magnetization prepared rapid gradient-echo; NEX, number of excitations or averages; PD, proton
density; R/L, right to left; SS-EPI, single-shot echo-planar imaging; TE, echo time; TI, inversion time; TR, repetition time; TSE, turbo spin-echo.
a0.1 mmol/kg dose injection with a gadolinium-chelated contrast agent. Use of a power injector is desirable at an injection rate of 3–5 cc/s.
bPostcontrast 3D T1-weighted images should be collected with equivalent parameters to precontrast 3D T1-weighted images.
cTSE¼ turbo spin-echo (Siemens & Philips) is equivalent to FSE (fast spin-echo; GE, Hitachi, Toshiba).
dFL2D¼ 2-dimensional fast low angle shot (FLASH; Siemens) is equivalent to the spoil gradient recalled echo (SPGR; GE) or T1-fast field echo (FFE; Philips), fast field echo (FastFE; Toshiba),
or the radiofrequency spoiled steady state acquisition rewound gradient echo (RSSG; Hitachi). A fast gradient echo sequence without inversion preparation is desired.
eIR-GRE¼ inversion-recovery gradient-recalled echo sequence is equivalent to MPRAGE¼magnetization prepared rapid gradient-echo (Siemens & Hitachi) and the inversion recovery
spoiled gradient-echo (IR-SPGR or Fast SPGR with inversion activated or BRAVO; GE), 3D turbo field echo (TFE; Philips), or 3D fast field echo (3D Fast FE; Toshiba).
fA 3D acquisition without inversion preparation will result in different contrast compared with MPRAGE or another IR-prepped 3D T1-weighted sequences and therefore should be avoided.
gIn the event of significant patient motion, a radial acquisition scheme may be used (eg, BLADE [Siemens], PROPELLER [GE], MultiVane [Philips], RADAR [Hitachi], or JET [Toshiba]);
however, this acquisition scheme can cause significant differences in ADC quantification and therefore should be used only if EPI is not an option. Further, this type of acquisition
takes considerably more time.
hDual echo PD/T2 TSE is optional for possible quantification of tissue T2. For this sequence, the PD echo is recommended to have a TE, 25 ms.
iAdvanced sequences can be substituted into this time slot, so long as 3D postcontrast T1-weighted images are collected between 4 and 8 minutes after contrast injection.
j3D FLAIR is an optional alternative to 2D FLAIR, with sequence parameters as follows per EORTC guidelines: 3D TSE/FSE acquisition; TE¼ 90–140 ms; TR¼ 6000–10 000 ms; TI¼ 2000–
2500 ms (chosen based on vendor recommendations for optimized protocol and field strength); GRAPPA≤ 2; fat saturation; slice thickness ≤1.5 mm; orientation sagittal or axial;
FOV≤ 250 mm×250 mm; matrix ≥244×244.
kChoice of TI should be chosen based on the magnetic field strength of the system (eg, TI≈ 2000 milliseconds for 1.5 T and TI≈ 2500 milliseconds for 3 T).
lIn order to ensure comparable SNR, older 1.5 T MR systems can use contiguous (no interslice gap) images with 5 mm slice thickness or increase NEX for slice thickness ≤4 mm.
nFor Siemens and Hitachi scanners. GE, Philips, and Toshiba scanners should use a TI¼ 400–450 milliseconds for similar contrast.
mFor Siemens and Hitachi scanners. GE, Philips, and Toshiba scanners should use a TR¼ 5–15 milliseconds for similar contrast.
pOlder model MR scanners that are not capable of .2 b values should use b¼ 0 and 1000 s/mm2.
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Three-dimensional IR-GRE, including MPRAGE or IR-SPGR, is
the most commonly used sequence for fast, 3-dimensional
evaluation of tumor burden and has been studied extensively
as a clinical tool in neuro-oncology for nearly 20 years.40 – 44
The use of inversion preparation provides superior gray
matter-to-white matter image contrast as well as significant
enhancement of vascular structures; however, there is concern
that inversion preparation may reduce the amount of lesion con-
spicuity. We considered potential use of 3-dimensional sequenc-
es without inversion preparation but felt the use of IR-GRE
sequences was warranted given their current widespread use
and extensive literature substantiating their clinical utility. Thus,
we recommend 3-dimensional isotropic T1-weighted IR-GRE ac-
quisition, which is available on almost all MR systems as part of
the standardized ADNI protocol, and agreement with previous
ACRIN, Alliance, and EORTC imaging guidelines for brain tumor
clinical trials.
We also considered the potential use of a 3-dimensional
turbo spin-echo (TSE) acquisition (eg, SPACE [Siemens] or
CUBE [General Electric]) instead of GRE, which studies have
suggested may provide a higher CNR between enhancing
tumor and background tissues.45 An inherent drawback of
3-dimensional GRE acquisition is the hyperintensity of blood
vessels after contrast agent injection, which may make tumor
segmentation more difficult due to increased signal from nor-
mal vasculature. The use of 3-dimensional TSE with motion-
sensitized driven-equilibrium preparation has been shown to
overcome this limitation by suppressing signal from blood.46
Despite the potential advantages of 3-dimensional TSE over
GRE, this sequence is not available on all MR systems, may re-
quire additional costs to purchase these sequences, and the
specific pulse sequences are not necessarily standardized
across vendors. Thus, we recommend 3-dimensional isotropic
T1-weighted images using a GRE acquisition, available on al-
most all MR systems as part of the standardized ADNI protocol
and in agreement with previous ACRIN, Alliance, and EORTC im-
aging guidelines for brain tumor clinical trials.
The use of precontrast and postcontrast T1-weighted imag-
es with matched sequence parameters also allows for use of
contrast-enhanced T1-weighted subtraction for tumor visuali-
zation and quantification of enhancing tumor. By subtracting
the voxel intensities obtained on precontrast T1-weighted
Table 2. Recommended 3T protocol
3D T1w Pre Ax 2D FLAIR Ax 2D DWI Ax 2D T2w 3D T1w Postb
Sequence IR-GREd,e TSEc EPIf
Co
n
tr
as
t
In
je
ct
io
n
a
TSEc IR-GREd,e
Plane Sagittal/axial Axial Axial Axial Axial/sagittal
Mode 3D 2D 2D 2D 3D
TR [ms] 2100g .6000 .5000 .2500 2100g
TE [ms] Min 100–140 Min 80–120 Min
TI [ms] 1100h 2500 1100h
Flip angle 108–158 908/≥1608 908/1808 908/≥1608 108–158
Frequency 256 ≥256 128 ≥256 256
Phase 256 ≥256 128 ≥256 256
NEX ≥1 ≥1 ≥1 ≥1 ≥1
FOV 256 mm 240 mm 240 mm 240 mm 256 mm
Slice thickness 1 mm 3 mm 3 mm 3 mm 1 mm
Gap/apacing 0 0 0 0 0
Diffusion options b¼ 0, 500, and 1000 s/mm2
≥3 directions
Parallel imaging Up to 2x Up to 2x Up to 2x Up to 2x Up to 2x
Scan time (approx) 5–8 min 4–5 min 3–5 min 3–5 min 5–8 min
Abbreviations: 3D, 3-dimensional; ADC, apparent diffusion coefficient; A/P, anterior to posterior; Ax, Axial; DWI, diffusion-weighted imaging; EPI,
echo-planar imaging; FLAIR, fluid-attenuated inversion recovery; FOV, field of view; IR-GRE, inversion-recovery gradient-recalled echo. MPRAGE,
magnetization-prepared rapid gradient-echo; NEX, number of excitations or averages; R/L, right to left; TSE, turbo spin-echo.
a0.1 mmol/kg or up to 20 cc (single, full dose) of MR contrast.
bPostcontrast 3D axial T1-weighted images should be collected with identical parameters to precontrast 3D axial T1-weighted images.
cTSE¼ turbo spin-echo (Siemens & Philips) is equivalent to FSE (fast spin-echo; GE, Hitachi, Toshiba).
dIR-GRE¼ inversion-recovery gradient-recalled echo sequence is equivalent to MPRAGE¼magnetization prepared rapid gradient-echo (Siemens &
Hitachi) and the inversion recovery spoiled gradient-echo (IR-SPGR or Fast SPGR with inversion activated or BRAVO; GE), 3D turbo field echo (TFE;
Philips), or 3D fast field echo (3D Fast FE; Toshiba).
eA 3D acquisition without inversion preparation will result in different contrast compared with MPRAGE or another IR-prepped 3D T1-weighted
sequences and therefore should be avoided.
fIn the event of significant patient motion, a radial acquisition scheme may be used (eg, BLADE [Siemens], PROPELLER [GE], MultiVane [Philips],
RADAR [Hitachi], or JET [Toshiba]); however, this acquisition scheme is can cause significant differences in ADC quantification and therefore should
be used only if EPI is not an option.
gFor Siemens and Hitachi scanners. GE, Philips, and Toshiba scanners should use a TR¼ 5–15 milliseconds for similar contrast.
hFor Siemens and Hitachi scanners. GE, Philips, and Toshiba scanners should use a TI¼ 400–450 milliseconds for similar contrast.
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images from postcontrast T1-weighted images, contrast agent
accumulation can be more easily identified and quantified. This
technique has been used in conjunction with MRI for brain tu-
mors starting in the early 1990s, when Suto et al47 and Lloyd
et al48 demonstrated the ability to identify enhancing tumors
in the presence of blood products. Subsequent studies over
the next few decades have further established the added
value of T1-weighted subtraction maps for lesion evaluation
during standard therapies, and a recent study clearly demon-
strated that enhancing tumor could be better identified on
T1-weighted subtraction maps during antiangiogenic thera-
py,49 where vascular permeability is markedly reduced. Addi-
tionally, T1-weighted subtraction maps have been shown to
reduce the interobserver variability in lesion volume quantifica-
tion, even in the presence of antiangiogenic therapies,14
suggesting that evaluation of tumor response may be signifi-
cantly improved through the use of T1-weighted subtraction
techniques.
Ranges of sequence parameters were chosen for volumetric
T1-weighted images based on known scanner and time
limitations. An isotropic resolution of 1 mm×1 mm×1 mm is
recommended with full brain coverage (field-of-view of
25.6 cm), but this may not be possible with older MR systems
or with adequate SNR at 1.5 T. Therefore, we recommend
acquiring volumetric T1-weighted images with a maximum res-
olution of 1.5 mm×1.5 mm×1.5 mm, particularly for scanners
at 1.5 T. Additionally, sagittal image acquisition is recommended
over axial acquisition because sagittal acquisition is faster due to
fewer required slices moving from left-to-right, although post-
contrast flow artifacts have occasionally been observed.
Although standard 3-dimensional T1-weighted GRE sequences
are preferred (eg, MPRAGE [Siemens & Hitachi] or IR-SPGR
[GE]), faster volumetric T1-weighted GRE sequences with internal
motion compensation may also be used under similar acquisi-
tion parameters to reduce artifacts (eg, BRAVO [GE] or VIBE
[Siemens]). Additional scan parameters and details are docu-
mented in Table 1.
Institutions may desire to collect postcontrast T1-weighted
images according to their own protocols in addition to the rec-
ommended 3-dimensional isotropic T1-weighted images (eg,
Table 3. Recommended 1.5T protocol
3D T1w Pre Ax 2D FLAIR Ax 2D DWI Ax 2D T2w 3D T1w Postb
Sequence IR-GREd,e TSEc EPIf
Co
n
tr
as
t
In
je
ct
io
n
a
TSEc IR-GREd,e
Plane Sagittal/axial Axial Axial Axial Sagittal/axial
Mode 3D 2D 2D 2D 3D
TR [ms] 2100g .6000 .5000 .3500 2100g
TE [ms] Min 100–140 Min 100–120 Min
TI [ms] 1100h 2200 1100h
Flip angle 108–158 908/≥1608 908/1808 908/≥1608 108–158
Frequency ≥172 ≥256 128 ≥256 ≥172
Phase ≥172 ≥256 128 ≥256 ≥172
NEX ≥1 ≥1 ≥1 ≥1 ≥1
FOV 256 mm 240 mm 240 mm 240 mm 256 mm
Slice thickness ≤1.5 mm ≤4 mm ≤4 mm ≤4 mm ≤1.5 mm
Gap/spacing 0 0 0 0 0
Diffusion optionsi b¼ 0, 500, and 1000 s/mm2
≥3 directions
Parallel imaging No Up to 2x Up to 2x Up to 2x No
Scan time (approximate) 5–10 min 4–5 min 3–5 min 3–5 min 5–10 min
Abbreviations: 3D, 3-dimensional; A/P, anterior to posterior; ADC, apparent diffusion coefficient; Ax, axial; DWI, diffusion-weighted imaging; EPI,
echo-planar imaging; FLAIR, fluid-attenuated inversion recovery; FOV, field of view; IR-GRE, inversion-recovery gradient-recalled echo; MPRAGE,
magnetization prepared rapid gradient-echo; NEX, number of excitations or averages; R/L, right to left; TSE, turbo spin-echo.
a0.1 mmol/kg or up to 20 cc (single, full dose) of MR contrast.
bPostcontrast 2D axial T1-weighted images should be collected with identical parameters to precontrast 2D axial T1-weighted images.
cTSE¼ turbo spin-echo (Siemens & Philips) is equivalent to FSE (fast spin-echo; GE, Hitachi, Toshiba).
dIR-GRE¼ inversion-recovery gradient-recalled echo sequence is equivalent to MPRAGE¼magnetization prepared rapid gradient-echo (Siemens
and Hitachi) and the inversion recovery spoiled gradient-echo (IR-SPGR or Fast SPGR with inversion activated or BRAVO; GE), 3D turbo field echo (TFE;
Philips), or 3D fast field echo (3D Fast FE; Toshiba).
eA 3D acquisition without inversion preparation will result in different contrast compared with MPRAGE or another IR-prepped 3D T1-weighted
sequences and therefore should be avoided.
fIn the event of significant patient motion, a radial acquisition scheme may be used (eg, BLADE [Siemens], PROPELLER [GE], MultiVane [Philips],
RADAR [Hitachi], or JET [Toshiba]); however, this acquisition scheme can cause significant differences in ADC quantification and therefore should be
used only if EPI is not an option.
gFor Siemens and Hitachi scanners. GE, Philips, and Toshiba scanners should use a TR¼ 5–15 milliseconds for similar contrast.
hFor Siemens and Hitachi scanners. GE, Philips, and Toshiba scanners should use a TI¼ 400–450 milliseconds for similar contrast.
iOlder model MR scanners that are not capable of .2 b-values should use b¼ 0 and 1000 s/mm2.
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2-dimensional, fat-saturated, T1-weighted TSE images). For
compliance with the proposed protocol, we recommend that ad-
ditional postcontrast sequences be acquired after 3-dimensional,
postcontrast T1-weighted images in order to ensure consistency
in terms of the timing of contrast agent injection and acquisition
of postcontrast T1-weighted images.
Use of Contrast Agents and Consistency of MR Scanners
Consistency in MR scanning hardware, software, contrast agent
dose, and contrast agent composition is absolutely imperative
for maximizing accurate and reproducible serial measurements
of tumor size. Patients involved in clinical trials should be
scanned on the same physical MRI scanner during routine
follow-up examinations to the extent that this is both econom-
ically and technically feasible. If this ideal recommendation is
not achievable, patients should at the very least be scanned
on MRI scanners with the same field strength. Although it
may be difficult to control the specific contrast agent used for
clinical trials, it is critical to use contrast agents with the same
chemical composition at each follow-up evaluation as baseline
to limit potential variability arising from differences in contrast
agent relaxivity (the amount of MR relaxation effects for a given
concentration of contrast agent). Additionally, the precise dose
and agent should be explicitly documented on the MR system
during acquisition or labeled in the DICOM header (eg, Con-
trast_BolusAgent (0018,0010)¼ 1.5 cc Gadovist).
Axial, 2-Dimensional, T2-Weighted Turbo Spin-echo
(Optional Dual-Echo Proton-Density/T2-Weighted TSE)
MRI
Damadian50 documented distinct differences in proton relaxation
rates between normal and cancerous tissues as early as 1971,
which were subsequently confirmed by various groups.51–53 Clin-
ical diagnoses and monitoring of the nonenhancing tumor are
often performed using T2-weighted images. Approximately
30%–40% of brain tumor patients exhibit nonenhancing tumor
progression prior to changes in contrast enhancement,32 and
some studies have described nonenhancing tumor growth and
infiltration prior to emergence of contrast-enhancing progressive
disease during antiangiogenic therapy.54 Further, T2 hyperintense
lesions are currently used to assess tumor burden in nonenhanc-
ing, low-grade glioma clinical trials. Therefore, use of T2-weighted
images in the proposed protocol is recommended for all clinical
brain tumor trials.
The protocol recommended for T2-weighted imaging was
based on the parameters from ADNI as well as ACRIN, Alliance,
and EORTC guidelines in existing trials. The recommended slice
thickness for 3 T scans is 3 mm with no interslice gap, and 1.5 T
scanners should acquire images up to 4 mm slice thickness with
no interslice gap. (Older scanners still in operation may be allowed
to acquire data up to a maximum of 5 mm slice thickness [con-
tiguous] or increase the number of averages with slice thicknesses
≤4 mm to ensure comparable SNR to other T2-weighted images
acquired with newer systems; however, this should be avoided if
possible.) The recommended echo train length (ETL) is between 8
and 16, since an increase in ETL both accelerates acquisition and
increases inaccuracies55 associated with T2 mapping when using
dual echo TSE to estimate tissue T2.
Timing of Contrast Agent Injection and Postcontrast
T1-weighted Images
A high CNR between tumor and surrounding tissue is critical for
precise measurement of tumor size. In addition to differences
in sequences and sequence parameters,56 the timing of con-
trast injection and acquisition of subsequent postcontrast
T1-weighted images can also lead to variability in tumor size
estimation. Dynamic contrast-enhanced imaging has shown
that the maximum contrast agent uptake typically occurs
and stabilizes between 4 and 8 minutes after contrast agent
application,57 suggesting that this may be the most effective
window for acquiring postcontrast T1-weighted images for
minimal variability in lesion size estimation caused by the tim-
ing of contrast agent administration. It is important to note
that one inherent limitation to implementing a minimal time
delay constraint is the preferential sensitivity to regions of the
tumor with higher vascular permeability and/or blood flow. To
standardize the minimal time between contrast agent injection
and acquisition of postcontrast T1-weighted images, we rec-
ommend acquiring T2-weighted images after injection and
just prior to postcontrast T1-weighted images. Presumably,
T2-weighted images utilizing spin-echo or TSE acquisitions
should be relatively insensitive to the presence of contrast
agent in the vasculature, assuming transient changes have al-
ready occurred (ie, assuming it is not during the first pass of the
bolus injection), such that RANO interpretation and volumetric
segmentation of T2-hyperintense regions should be minimally
impacted.
Axial, 2-Dimensional, T2-Weighted Fluid-Attenuated
Inversion Recovery) MRI
T2-weighted fluid-attenuated inversion recovery (FLAIR) MRI
uses a combination of T1- and T2-weighting to suppress the sig-
nal originating from bulk fluid including cerebrospinal fluid.
T2-weighted FLAIR techniques increase lesion conspicuity, allow-
ing for better visualization of vasogenic edema, surgery-induced
and radiation- induced gliosis and infiltrating tumor, particularly
near the cortex and ventricles where cerebrospinal fluid can in-
hibit lesion detection. Additionally, T2-weighted FLAIR sequences
(or T2-weighted images) are recommended for determination of
nonenhancing tumor progression using RANO criteria.
The preferred protocol for T2-weighted FLAIR imaging was
based on guidelines from the EORTC, ACRIN, and Alliance. Sim-
ilar to T2-weighted MRI, the recommended slice thickness for
3 T scans is 3 mm with no interslice gap, and 1.5 T scanners
should acquire images up to 4 mm slice thickness with no inter-
slice gap. Older scanners still in operation may be allowed to
acquire data up to a maximum of 5 mm slice thickness (contig-
uous) or increase the number of averages with slice thicknesses
≤4 mm to ensure comparable SNR to other T2-weighted FLAIR
images acquired with newer systems. Also note that T2-weighted
FLAIR MR images have intrinsically less SNR compared with
standard T2-weighted MR images. The recommended ETL for
T2-weighted FLAIR images is between 8 and 16.
Three-dimensional T2-weighted FLAIR techniques are com-
monly used on newer MR systems but may not be available on
all MR systems. A 3-dimensional acquisition allows for slice re-
orientation in all 3 anatomical planes, the potential for
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quantification of T2-hyperintense lesion volumes, and less sen-
sitivity to flow artifacts compared with 2D sequences. Given
that 3-dimensional acquisition is not universally available, the
use of this technique, while strongly endorsed, is optional. Pro-
tocols or studies considering the use of 3D FLAIR should use the
EORTC-recommended parameters listed in the footnotes in
Table 1.
Axial 2-Dimensional Diffusion-Weighted Imaging
Diffusion-sensitive MR techniques are routinely acquired as part
of standard brain MRI protocols, primarily due to the high sen-
sitivity to early ischemic injury as well as infection/abscess. DWI
is sensitive to microscopic, subvoxel water motion, resulting in
relatively restricted diffusion in areas of tumor due to tightly
packed tumor cells. Measures of the apparent diffusion coeffi-
cient (ADC) can be estimated from the DWI data, reflecting the
general magnitude of water motion. In brain tumors, ADC has
been shown to be a surrogate for cellularity in certain circum-
stances, with ADC inversely correlated with tumor cell densi-
ty,58 – 61 suggesting that DWI measures of ADC may be a
useful biomarker for quantifying treatment response.62
The recommended DWI protocol for routine evaluations is
largely based on the EORTC, ACRIN, and Alliance-recommended
protocols as well as the International Society for Magnetic
Resonance in Medicine and NCI consensus recommendations
from 2008.62 Specifically, we recommend that 3 b-values be
collected, one at b¼ 0 s/mm2 (no diffusion weighting), one
mid-range b-value of 500 s/mm2, and one higher b-value at
b¼ 1000 s/mm2. These images should be collected in at least
3 directions (ie, x, y, and z orientations with respect to the MR
system frame of reference). Older MR scanners that are not ca-
pable of obtaining 3 or more unique b-values should use b¼ 0
and b¼ 1000 s/mm2. The high b-value for routine DWI in clin-
ical trials should be limited to b¼ 1000 s/mm2, resulting in a
relative signal intensity of 37% of available MR signal if tissue
has an ADC of 1 mm2/millisecond, commonly associated with
mean diffusivity of normal white matter. The recommended
slice thickness for 3 T scans is 3 mm with no interslice gap,
and 1.5 T scanners should acquire images up to 4 mm slice
thickness with no interslice gap. Older scanners still in operation
may be allowed to acquire data up to a maximum of 5 mm
slice thickness (contiguous) or increase the number of averages
with slice thicknesses ≤4 mm to ensure comparable SNR echo-
planar imaging (EPI) should be used when available. In the
event of significant patient motion, a radial acquisition scheme
may be used (eg, BLADE [Siemens], PROPELLER [GE], MultiVane
[Philips], RADAR [Hitachi], or JET [Toshiba]); however, this acqui-
sition scheme can cause significant differences in ADC quanti-
fication and therefore should be used only if EPI is not an
option. Additionally, radial acquisition techniques may require
considerably more time.
Conclusion
The proposed recommendations for brain tumor MRI acquisi-
tion reflect a balance of state-of-the-art imaging technology
with techniques that are practically employable across the ma-
jority of imaging centers involved in multicenter clinical trials.
We specifically recommend this protocol for use in multicenter
clinical trials to reduce variability associated with response as-
sessment, but we also encourage the use of this protocol in
routine clinical practice where it will allow intra-institutional
comparisons. The protocol was designed to allow flexibility in
terms of adding subsequent imaging techniques, such as the
addition of perfusion MRI prior to acquisition of postcontrast
3D T1-weighted images, the addition of susceptibility-weighted
or gradient-echo acquisition before contrast injection, or acqui-
sition of postcontrast, 2D T1-weighted TSE images following
postcontrast 3D T1-weighted image acquisition. The current
recommendations were designed to serve as a benchmark
for comparison to future improvements and evaluations.
The current recommendations solely involve acquisition of
MR images and do not provide guidelines for the clinical inter-
pretation or quantitation of tumor extent for the purposes of
response evaluation. The current protocols were designed to
be flexible and allow for both current RANO evaluations as
well as the potential for future improvements including volu-
metric analyses.
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